Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,521 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Irie A, Kawahara K, Yatsuda J, Hamada A, Jono H, Yoshida K, Tsunoda T, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y. Tomita Y, et al. Among authors: shinohara m. Clin Cancer Res. 2013 Aug 15;19(16):4508-20. doi: 10.1158/1078-0432.CCR-13-0197. Epub 2013 May 28. Clin Cancer Res. 2013. PMID: 23714729
Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis.
Yoshitake Y, Nakatsura T, Monji M, Senju S, Matsuyoshi H, Tsukamoto H, Hosaka S, Komori H, Fukuma D, Ikuta Y, Katagiri T, Furukawa Y, Ito H, Shinohara M, Nakamura Y, Nishimura Y. Yoshitake Y, et al. Among authors: shinohara m. Clin Cancer Res. 2004 Oct 1;10(19):6437-48. doi: 10.1158/1078-0432.CCR-04-0841. Clin Cancer Res. 2004. PMID: 15475430
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.
Yoshitake Y, Fukuma D, Yuno A, Hirayama M, Nakayama H, Tanaka T, Nagata M, Takamune Y, Kawahara K, Nakagawa Y, Yoshida R, Hirosue A, Ogi H, Hiraki A, Jono H, Hamada A, Yoshida K, Nishimura Y, Nakamura Y, Shinohara M. Yoshitake Y, et al. Among authors: shinohara m. Clin Cancer Res. 2015 Jan 15;21(2):312-21. doi: 10.1158/1078-0432.CCR-14-0202. Epub 2014 Nov 12. Clin Cancer Res. 2015. PMID: 25391695 Clinical Trial.
An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs.
Hirayama M, Tomita Y, Yuno A, Tsukamoto H, Senju S, Imamura Y, Sayem MA, Irie A, Yoshitake Y, Fukuma D, Shinohara M, Hamada A, Jono H, Yuba E, Kono K, Yoshida K, Tsunoda T, Nakayama H, Nishimura Y. Hirayama M, et al. Among authors: shinohara m. Oncoimmunology. 2016 Jan 4;5(6):e1123368. doi: 10.1080/2162402X.2015.1123368. eCollection 2016 Jun. Oncoimmunology. 2016. PMID: 27471607 Free PMC article.
Cancer prevention with semi-allogeneic ES cell-derived dendritic cells.
Fukuma D, Matsuyoshi H, Hirata S, Kurisaki A, Motomura Y, Yoshitake Y, Shinohara M, Nishimura Y, Senju S. Fukuma D, et al. Among authors: shinohara m. Biochem Biophys Res Commun. 2005 Sep 16;335(1):5-13. doi: 10.1016/j.bbrc.2005.06.096. Biochem Biophys Res Commun. 2005. PMID: 16026756
Selective inhibition of nuclear factor-κB by nuclear factor-κB essential modulator-binding domain peptide suppresses the metastasis of highly metastatic oral squamous cell carcinoma.
Tanaka T, Nakayama H, Yoshitake Y, Irie A, Nagata M, Kawahara K, Takamune Y, Yoshida R, Nakagawa Y, Ogi H, Shinriki S, Ota K, Hiraki A, Ikebe T, Nishimura Y, Shinohara M. Tanaka T, et al. Among authors: shinohara m. Cancer Sci. 2012 Mar;103(3):455-63. doi: 10.1111/j.1349-7006.2011.02174.x. Epub 2012 Jan 16. Cancer Sci. 2012. PMID: 22136381 Free PMC article.
1,521 results